Among newly diagnosed UK Type 2/3 SMA patients under 18, 65% now choose oral risdiplam over intrathecal nusinersen.

Spinal muscular atrophy is a motor neuron disease caused by SMN1 loss, with SMN2 copy number acting as the severity modifier. The UK added SMA to its national newborn screening programme in 2021, the first country in Europe to do so, screening via a day-5 heel-prick SMN1 homozygous-deletion PCR test, with positive results notified to Great Ormond Street Hospital or a regional SMA centre within 24 to 48 hours. Roughly 20-25 cases are detected through newborn screening annually, and pre-symptomatic treatment with gene therapy is now standard practice at six NHS-designated SMA gene therapy centres.

The living UK SMA cohort is estimated at around 1,000 patients across all types: roughly 200 with Type 1, historically high mortality and now largely newborn-screening detected, 400 with Type 2, the largest living cohort, 350 with Type 3, and 50 adult-onset Type 4. NHS Highly Specialised Services commission SMA management through four regional networks, Manchester, GOSH/Evelina, Birmingham/Alder Hey, and Edinburgh, and all three approved therapies, onasemnogene abeparvovec, risdiplam, and nusinersen, are available on the NHS with confidential commercial arrangements. For newly diagnosed Type 2/3 patients under 18, a 2023 NHS centre survey found 65% of families choosing oral risdiplam over intrathecal nusinersen.

Screening solved diagnosis; therapy choice is now shifting toward the oral option.

Five questions this report answers:

Q1 - How has the UK's 2021 newborn-screening programme changed the pre-symptomatic SMA treatment population?

Q2 - How is the roughly 1,000-patient UK SMA cohort distributed across Type 1 through 4?

Q3 - Where does unmet need remain in UK SMA once screening and NICE-recommended therapies exist?

Q4 - Which four NHS regional networks commission SMA management and gene therapy access?

Q5 - Why are 65% of newly diagnosed under-18 Type 2/3 patients choosing risdiplam over nusinersen?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#SMA #NewbornScreening #NHS #NICE #UK #RareDisease

Live report page:  https://axlrx.ai/spinal-muscular-atrophy/uk/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                    hello@axlrx.ai

Web-                    https://axlrx.ai/

Saudi Arabia sees 200-250 new SMA births a year, yet a legacy cohort of 800-1,200 GCC patients remains ineligible for gene therapy entirely.

Spinal muscular atrophy incidence in the GCC runs 1 in 6,000 to 8,000 live births versus roughly 1 in 10,000 globally, elevated by consanguinity increasing the odds of homozygous SMN1 deletion. Saudi Arabia alone sees an estimated 200-250 new SMA births annually against roughly 250,000 total births, with the UAE contributing 30-35 and Qatar 20-25, a combined GCC total near 300-350 new cases a year. Newborn screening is converting these from symptomatic diagnoses to pre-symptomatic identification at very different rates by country: an estimated 90% in Saudi Arabia, 85% in the UAE, 75% in Qatar, and below 50% across the remaining states.

The clinical stakes of that screening gap are large. Pre-screening SMA Type 1 median survival ran near 2 years; with newborn-screening identification and immediate Zolgensma treatment, survival in the NURTURE cohort approaches that of unaffected children, and pre-symptomatic infants at centres including KAMC, KFSH&RC, Sidra Medicine, and SKMC are reaching normal motor milestones. Alongside this pre-symptomatic cohort sits a distinct unmet-need population: an estimated 800-1,200 GCC SMA Type 2/3 patients diagnosed before screening existed, now teenagers and adults with established motor disability. These patients are ineligible for gene therapy on age and weight criteria and depend on chronic nusinersen or risdiplam, or remain untreated, while physical therapy and respiratory support outside tertiary centres stays limited.

Screening is solving the newborn cohort; the legacy cohort still needs an answer.

Five questions this report answers:

Q1 - How does GCC newborn-screening coverage vary by country, and what does that mean for the near-term Zolgensma-eligible population?

Q2 - What is the size and treatment status of the pre-NBS Type 2/3 adult SMA population across the GCC?

Q3 - What non-drug infrastructure, like physical therapy and respiratory support, constrains SMA outcomes outside GCC tertiary centres?

Q4 - How many new SMA cases does the GCC see annually, and how is that split by country?

Q5 - Which GCC centres, including KAMC and Sidra Medicine, are delivering pre-symptomatic gene therapy today?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#SMA #SpinalMuscularAtrophy #GCC #NewbornScreening #RareDisease #DiseaseLandscape

Live report page:  https://axlrx.ai/spinal-muscular-atrophy/gcc/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                    hello@axlrx.ai

Web-                    https://axlrx.ai/

Sickle cell disease cuts US median life expectancy to about 54 years, a 22-year gap, yet hydroxyurea still reaches only a quarter of eligible patients.

Sickle cell disease is an inherited hemoglobinopathy affecting roughly 100,000 Americans, occurring in about 1 in 365 Black or African American births. The homozygous HbSS genotype accounts for around 60% to 65% of cases and carries the most severe phenotype; HbSC disease, about 25%, and HbS/beta-thalassemia, the remainder, are generally milder, with severity tracking residual beta-globin production. Polymerisation of deoxygenated haemoglobin S deforms red cells, driving haemolysis, vaso-occlusion and progressive organ injury from early childhood onward.

The clinical signature is the recurrent vaso-occlusive crisis, layered over cumulative damage such as acute chest syndrome, stroke, pulmonary hypertension and kidney decline. A US modelling study put median life expectancy at about 54 years versus 76 years without the disease, a 22-year gap. Hydroxyurea reduces crises and mortality but reaches only 25% to 30% of eligible patients, the single largest treatment gap in the disease. An estimated 20,000 to 30,000 patients with severe, recurrent disease form the subset for whom one-time gene therapy is now clinically relevant.

A 22-year life-expectancy gap persists despite a therapy that only a quarter use.

Five questions this report answers:

Q1 - How large is the US sickle cell population by genotype and severity?

Q2 - What vaso-occlusive and organ-damage burden drives the 22-year life-expectancy gap?

Q3 - Which patient segment anchors commercial strategy for one-time gene therapy?

Q4 - How many Americans live with sickle cell disease today?

Q5 - Why does hydroxyurea reach only a quarter of eligible patients?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#SickleCellDisease #SCD #GeneTherapy #RareDisease #HealthEquity #USHealthcare

Live report page:  https://axlrx.ai/sickle-cell-disease/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                    hello@axlrx.ai

Web-                    https://axlrx.ai/

Saudi Arabia alone carries an estimated 140,000-200,000 sickle cell patients, while mandatory premarital screening cuts new HbSS births 15-20% a year.

Sickle cell disease burden in the GCC is disproportionate on a global scale: Saudi Arabia alone carries an estimated 140,000-200,000 patients, reflecting carrier rates of 6-7% in the Eastern Province and 3-4% nationally, with significant HbSS and HbSS/HbC compound heterozygosity; Bahrain reports 2-3% adult prevalence and parts of Oman 3-5%. This makes the GCC one of the highest per-capita SCD burden regions outside sub-Saharan Africa, a legacy of historic trade-route population mixing along the Persian Gulf and Arabian Sea. Mandatory premarital carrier screening, in place nationally in Saudi Arabia, has reduced new HbSS births by an estimated 15-20% annually since implementation, the single most effective GCC-specific intervention to date.

Inadequately treated GCC SCD patients experience 8-12 vaso-occlusive crisis episodes a year and 4-6 hospital admissions annually for severe disease, alongside substantial chronic organ damage: pulmonary hypertension in an estimated 20% of echo-screened patients, avascular necrosis of the hip or shoulder in 30-40%, and stroke history in roughly 10%, lower than comparable US cohorts and attributed to transfusion exchange programmes at major centres. Annual cost per GCC SCD patient runs SAR 180,000-300,000 including hospitalisation, transfusion, and chelation. The patient pathway typically runs from newborn screening through paediatric haematology to adult transition at age 18-21, a transition poorly managed outside KFSH&RC, KAMC, and AUH, which maintain structured adult SCD programmes.

Premarital screening is cutting incidence, but the existing patient population still needs specialist care.

Five questions this report answers:

Q1 - What is the true scale of the GCC SCD population, and how is premarital screening reshaping it?

Q2 - How does the adult transition gap at age 18-21 affect SCD treatment continuity across the GCC?

Q3 - What does the SFDA registration timeline mean for gene therapy commercial readiness in the GCC?

Q4 - How much does one GCC sickle cell patient cost the health system a year?

Q5 - Which three GCC centres maintain structured adult sickle cell haematology programmes today?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#SickleCellDisease #GCC #SaudiArabia #PremaritalScreening #RareDisease #DiseaseLandscape

Live report page:  https://axlrx.ai/sickle-cell-disease/gcc/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                    hello@axlrx.ai

Web-                    https://axlrx.ai/

NICE's Casgevy recommendation (TA1044) carries a £300-600 million annual NHS exposure across just 200-300 eligible severe patients a year.

Sickle cell disease is the UK's largest haemoglobinopathy population and the largest in Europe: an estimated 15,000-17,000 patients, concentrated at specialist centres in London (Barts, King's, Imperial, Homerton, roughly 6,000 patients combined), Birmingham Heartlands (roughly 2,000), Manchester, Bristol, and Nottingham. The NHS has screened for SCD and sickle cell trait since 1999, so virtually all UK SCD patients are now diagnosed at birth; roughly 350-500 new SCD births occur annually, reflecting immigration patterns from Sub-Saharan Africa and the Caribbean.

Hydroxycarbamide is recommended for moderate-to-severe disease under the British Society for Haematology's 2018 guideline, generally three or more vaso-occlusive crises a year or significant organ damage. A 2022 NHS audit found roughly half of eligible UK patients on hydroxyurea, better than the US at 25-30% but below guideline target, with adherence, fertility concerns, and prescriber reluctance cited as barriers. Access changed in November 2023, when MHRA granted conditional approval to Casgevy, the first CRISPR gene therapy licensed in the UK for sickle cell disease. NICE's TA1044 recommends managed access for severe patients 12 and over who cannot access a matched-donor transplant, against a price exceeding £1.5 million and a £300-600 million annual NHS exposure.

One therapy, hydroxyurea, is about to be reshaped by a £300-600 million access decision.

Five questions this report answers:

Q1 - How is the UK's 15,000-17,000 SCD population distributed across specialist centres like Barts and Birmingham?

Q2 - Why does only half of hydroxyurea-eligible UK SCD patients actually receive it?

Q3 - What are the managed-access terms and budget impact of Casgevy's NICE recommendation (TA1044)?

Q4 - How many new SCD births does the UK see each year, and from where?

Q5 - Why does Lyfgenia remain unavailable to UK sickle cell patients despite US approval?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#SickleCellDisease #Casgevy #NICE #NHS #GeneTherapy #RareDisease

Live report page:  https://axlrx.ai/sickle-cell-disease/uk/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                    hello@axlrx.ai

Web-                    https://axlrx.ai/

Psoriasis affects 7.55 million US adults, yet only one in five carries the moderate-to-severe disease that reaches biologics.

Psoriasis prevalence among US adults is 3.0%, or an estimated 7.55 million adults, and has been stable since 2003 per NHANES data from 2011 to 2014 (Armstrong et al., PMID 34190957). Prevalence is not uniform: it runs highest in White adults at 3.6% and lowest in Black adults at 1.5%, a gradient that shapes diagnosis rates and access. Plaque psoriasis is the dominant morphology, and disease severity, not headcount, governs where systemic and biologic therapy is actually used across the population.

Two clinical facts drive commercial concentration. First, only a minority of patients, roughly one in five per National Psoriasis Foundation estimates, carry moderate-to-severe disease qualifying for systemic therapy, defined in trials as PASI of 12 or above, body surface area of 10% or more, or IGA of 3 or above. Second, psoriatic arthritis co-occurs in 19.7% of psoriasis patients (North America 19.5%, Alinaghi et al., PMID 29928910), pulling a large subgroup toward mechanisms with joint efficacy and rheumatology co-management. Standard care escalates from topicals and phototherapy through conventional systemics to biologics and oral TYK2 therapy.

Severity, not prevalence, decides who reaches biologic therapy.

Five questions this report answers:

Q1 - Of 7.55 million affected adults, how many are genuinely biologic-eligible and treated today?

Q2 - How does the 19.7% psoriatic arthritis overlap redirect mechanism choice and specialty ownership?

Q3 - What does the White-to-Black prevalence gradient imply for underdiagnosis and access equity?

Q4 - How common is plaque psoriasis in the US, and which patients reach systemic therapy?

Q5 - What clinical thresholds (PASI, BSA, IGA) define moderate-to-severe psoriasis eligible for systemic therapy?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#Psoriasis #Biologics #Dermatology #PsoriaticArthritis #USHealthcare #DiseaseLandscape

Live report page:  https://axlrx.ai/psoriasis/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                    hello@axlrx.ai

Web-                    https://axlrx.ai/

Roughly 70-80% of the 5,000-10,000 US Pompe patients have late-onset disease, yet years often pass before a blood-spot test confirms it.

Pompe disease is an autosomal-recessive metabolic myopathy caused by deficiency of the enzyme acid alpha-glucosidase, leading to glycogen buildup in skeletal, respiratory and, in infants, cardiac muscle. The US Pompe population is estimated at 5,000 to 10,000 patients. Late-onset disease, defined by residual enzyme activity above roughly 1%, accounts for an estimated 70% to 80% of patients and spans a wide phenotype, from near-asymptomatic to wheelchair- and ventilator-dependent. Infantile-onset Pompe, with near-absent enzyme activity, presents within the first months of life with hypertrophic cardiomyopathy and profound low muscle tone, and was historically fatal within the first year without treatment.

Two features define the late-onset landscape. First, diagnosis is slow: patients are frequently worked up for limb-girdle muscular dystrophy or an unexplained myopathy for years before a dried-blood-spot enzyme assay confirms Pompe. Second, respiratory decline, not limb weakness, is the clinical clock; severity tracks disease duration, so earlier-onset patients reach wheelchair and ventilator dependence sooner. Newborn screening is now expanding the pre-symptomatic identified pool and reshaping when and where enzyme replacement therapy begins.

Diagnostic delay, not treatment scarcity, is what defines late-onset Pompe's commercial gap.

Five questions this report answers:

Q1 - What is the size and phenotype split of the US late-onset Pompe population?

Q2 - Where does the diagnostic delay in late-onset Pompe disease come from?

Q3 - Why does respiratory decline, not motor weakness, drive Pompe treatment timing?

Q4 - How does late-onset Pompe differ from infantile-onset Pompe disease?

Q5 - Why is late-onset Pompe disease so often diagnosed late?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#PompeDisease #GAA #RareDisease #NewbornScreening #Neuromuscular #USHealthcare

Live report page:  https://axlrx.ai/pompe-disease/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                    hello@axlrx.ai

Web-                    https://axlrx.ai/

Roughly a quarter of UK Pompe patients on long-term ERT are inadequate responders, the target population for avalglucosidase alfa.

Pompe disease is caused by acid alpha-glucosidase (GAA) deficiency, and the UK Pompe Consortium, an academic-clinical network spanning GSTT/King's, Manchester, Birmingham, Addenbrooke's, and Edinburgh, coordinates shared care, a national registry, and research across an estimated 200 UK patients combining infantile-onset and late-onset disease. Unlike some Gulf markets, the NHS newborn-screening programme does not currently include Pompe disease, so infantile-onset cases, roughly 12-18 a year, are diagnosed symptomatically; late-onset disease is typically diagnosed 5-10 years after first symptom, frequently misread initially as a limb-girdle myopathy.

The UK LOPD diagnostic pathway runs from unexplained proximal myopathy and elevated creatine kinase through metabolic genetics referral to a dried-blood-spot GAA enzyme assay and confirmatory gene sequencing, offered free through the NHS Genomic Medicine Service, a journey the UK Pompe Consortium estimates at 3-8 years from first symptom. Alglucosidase alfa has never been formally appraised by NICE; enzyme replacement therapy continuation is instead governed by NHS clinical commissioning policy, which requires lung-function and walk-test monitoring at baseline, 12, and 24 months, with continuation contingent on at least 10% improvement or stabilisation. Roughly 60% of patients on ERT for more than five years show continued stabilisation, but around 25%, an estimated 45-50 UK patients, show decline despite treatment and are the immediate target for avalglucosidase alfa, already NICE-recommended as TA821.

A quarter of treated patients keep declining; next-generation ERT already has NICE backing.

Five questions this report answers:

Q1 - How does the UK Pompe Consortium's network shape diagnosis across the roughly 200-patient population?

Q2 - What is the size of the inadequate-ERT-responder subset now eligible for avalglucosidase alfa (TA821)?

Q3 - What drives the 3-8 year UK diagnostic delay for late-onset Pompe disease?

Q4 - Why doesn't NHS newborn screening currently include Pompe disease, unlike some Gulf markets?

Q5 - What continuation criteria, like lung-function and walk-test results, govern ongoing NHS ERT funding?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#PompeDisease #NICE #NHS #RareDisease #EnzymeReplacementTherapy #UK

Live report page:  https://axlrx.ai/pompe-disease/uk/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                    hello@axlrx.ai

Web-                    https://axlrx.ai/

Saudi newborn screening will detect 25-35 infantile Pompe cases yearly, while late-onset patients are still found at 55-65% FVC.

Pompe disease incidence in the GCC runs 1 in 20,000 to 30,000 live births versus roughly 1 in 40,000 globally, elevated by consanguinity; infantile-onset Pompe represents a larger proportion of GCC cases than in global series, consistent with the region's consanguinity pattern. Saudi Arabia added Pompe disease, via a GAA dried-blood-spot assay, to its national newborn screening programme in 2021, with an expected 25 to 35 combined GCC infantile-onset detections annually. The KFSH&RC metabolic genetics programme has treated approximately 120 Pompe patients of all subtypes over 15 years, the region's largest single-centre experience.

Late-onset Pompe disease follows a very different path: GCC patients typically present at age 20 to 40 with progressive proximal myopathy or respiratory decline, and diagnosis often comes only after multiple rheumatology or neurology assessments have first considered, and excluded, limb-girdle muscular dystrophy. Baseline forced vital capacity at diagnosis is estimated at 55% to 65% predicted, indicating advanced disease by the time enzyme assay and genetic confirmation finally occur. Enzyme replacement therapy requires specialist infusion capacity available at only 6 to 8 centres across all six GCC countries, and patients outside these cities travel 100 to 300km for biweekly infusions, though KFSH&RC piloted a home infusion programme in 2022.

Late-onset Pompe hides behind a limb-girdle muscular dystrophy diagnosis for years.

Five questions this report answers:

Q1 - How is Saudi Arabia's 2021 newborn screening expansion changing the infantile-onset diagnosed population?

Q2 - Why do late-onset Pompe patients pass through a limb-girdle muscular dystrophy detour?

Q3 - Which GCC metabolic centres have ERT infusion capacity, and what does that gap mean for access?

Q4 - How do newborn screening and diagnostic delay reshape the addressable GCC Pompe market?

Q5 - Why does GCC Pompe disease incidence run 33-100% above the global rate?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#PompeDisease #RareDisease #NewbornScreening #GCCHealthcare #DiseaseLandscape

Live report page:  https://axlrx.ai/pompe-disease/gcc/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                    hello@axlrx.ai

Web-                    https://axlrx.ai/

PNH's 800-1,200 patient EVH subpopulation, not the full 15,000-20,000 prevalence estimate, defines the complement-inhibitor era opportunity.

PNH is a clonal haematopoietic stem cell disorder caused by somatic PIG-A mutation, leading to GPI-anchor deficiency and complement-mediated red blood cell lysis. US prevalence is estimated at 15,000 to 20,000 patients, median age 35, with equal sex distribution. The disease spans three clinically and commercially distinct axes, haemolysis-dominant, aplasia-dominant, and thrombotic PNH, each requiring different treatment approaches and commercial micro-segmentation rather than a single undifferentiated patient count.

Mean diagnostic delay is 2.4 years, driven by misdiagnosis as autoimmune haemolytic anaemia, aplastic anaemia, or MDS. Approximately 15 to 20% of aplastic anaemia patients harbour PNH clones, forming the largest undiagnosed patient pool. Anti-C5 therapy has dramatically reduced thrombotic mortality, but 800 to 1,200 patients with extra-vascular haemolysis, persistent anaemia despite IV complement inhibition, define the residual unmet need and the commercial rationale for proximal complement inhibitors such as iptacopan.

The EVH subpopulation, not total prevalence, is where the commercial case actually lives.

Five questions this report answers:

Q1 - What is the size and clinical characterisation of the EVH-dominant US PNH subpopulation?

Q2 - What is the diagnostic pathway for PNH, and where are the largest undiagnosed patient pools?

Q3 - How does the PNH disease spectrum drive different treatment decisions and commercial micro-segmentation?

Q4 - Which US PNH subpopulations represent the greatest unmet commercial need today?

Q5 - What share of aplastic anaemia patients actually harbour an undiagnosed PNH clone?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#PNH #US #RareDisease #DiseaseLandscape #ComplementInhibitor #Hematology

Live report page:  https://axlrx.ai/pnh/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                    hello@axlrx.ai

Web-                    https://axlrx.ai/